PMN310 is a humanized monoclonal antibody (mAb) designed and developed to selectively target only soluble amyloid-beta ...

ProMIS Neurosciences (PMN) announced important progress in the PRECISE-AD Phase 1b clinical trial with the dosing of multiple patients with its ...

The UV-curable coatings market is witnessing significant expansion, driven by the increasing demand for environmentally friendly coatings across various industries, including automotive, electronics, ...